A student-run resource for reliable reports on the latest law and technology news

Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott 

Written By: Hyeongsu Park - Edited By: Kendra Albert

The market for therapeutic antibodies is projected to reach hundreds of billion dollars within the next several years. In Centocor v. Abbott, the Court of Appeals for the Federal Circuit (“Federal Circuit”) held that a patentee cannot claim an antibody unless the specification describes it, even if he/she fully characterizes the antigen, and the court vacated a $1.67 billion jury verdict, the largest patent infringement award in U.S. history.

Read More...

Posted On Mar - 13 - 2014 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter
  • GooglePlay
Icon-news

Federal Circuit Flas

By Steven Wilfong Multimedia car system patents ruled as unenforceable based ...

Icon-news

Flash Digest: News i

By Viviana Ruiz Converse attempts to protect iconic Chuck Taylor All ...

silkroad_fbi_110813

Silk Road Founder Lo

By Travis West — Edited by Mengyi Wang Order, United States ...

free-speech

Trademark Infringeme

By Yunnan Jiang – Edited by Paulius Jurcys Brief for the ...

Twitter.png?t=20130219104123

Twitter goes to cour

By Jens Frankenreiter – Edited by Michael Shammas Twitter, Inc. vs. ...